Skip to main content

Major Depressive Disorder

The US Food and Drug Administration (FDA) recently granted Usona Institute, Madison, Wisconsin, the Breakthrough Therapy designation for psilocybin in the treatment of patients with major depressive disorder (MDD).
At both lower and higher doses, a yoga and breathing intervention improved symptoms of depression and anxiety in a group of people with major depressive disorder (MDD), according to a study published recently in the Journal of Psychiatric Practice.
People with mood or anxiety disorders demonstrate shared abnormalities in brain regions involved in emotional and cognitive control, according to a meta-analysis of brain scans published online in JAMA Psychiatry.
Deep brain stimulation of the subcallosal cingulate appears to offer sustained antidepressant efficacy and long-term safety for patients with treatment-resistant depression for up to 8 years.
Antidepressant use appears to be safe, according to a systematic umbrella review of 45 meta-analyses spanning more than 1000 observational studies. Researchers published findings from their review online in JAMA Psychiatry.
Two members of the Psych Congress Steering Committee have been featured on an ABC News podcast which grew out of a newsman's newfound interest in meditation.
Listen as Psych Congress Steering Committee member Charles Raison, MD, discusses a book he coauthored, The New Mind-Body Science of Depression, with David Van Nuys, PhD, on Shrink Rap Radio.
Listen to Charles Raison, MD, discuss his JAMA Psychiatry study examining the relationship between inflammation and depression.
Back to Top